Full history for every metric is available with a Kvantra account
Aidigong Maternal & Child Health Limited (0286.HK)
Key financial summary
Financials in HKD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | HKD m | 377 | 619 | 620 | 663 | 703 | 555 | 522 |
| Operating profit | HKD m | -106 | -156 | |||||
| Net profit | HKD m | 2 | 11 | -381 | 5 | -165 | -177 | -193 |
| EPS reported | HKD | -1.43 | -1.53 | |||||
| Operating cashflow per share | HKD | 0.67 | 0.67 | |||||
| Capex per share | HKD | 0.29 | 0.29 | |||||
| FCF per share | HKD | 0.37 | 0.37 | |||||
| Free cash flow | HKD m | 46 | 34 | |||||
| Net debt | HKD m | 291 | 447 | |||||
| Book value equity | HKD m | 738 | 741 | |||||
| Book value per share | HKD | 5.94 | 6.15 | |||||
| Number of shares | m | 124.11 | 120.42 | |||||
| DPS (TTM paid) | HKD | 0.00 | 0.00 |
Financial summary
Financials in HKD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.52 | 0.34 | |||||
| P/S LTM | x | 2.02 | 0.48 | |||||
| P/FCF LTM | x | 24.14 | 7.37 | |||||
| EV/EBITDA LTM | x | 24.00 | -19.32 | |||||
| EV/Sales LTM | x | 2.98 | 1.34 | |||||
| Earnings Yield LTM | % | -15.87% | -109.13% | |||||
| FCF Yield | % | 4.14% | 13.56% | |||||
| Quality | ||||||||
| ROE | % | -24.05% | -21.58% | |||||
| ROIC | % | -6.07% | -6.07% | |||||
| Operating margin | % | -19.13% | -19.13% | |||||
| Gross margin | % | 21.82% | 21.82% | |||||
| FCF/Sales | % | 8.35% | 8.35% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -21.15% | -20.70% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | -75.41% | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | 0.08 | 0.04 | |||||
| Net Debt/EBITDA | x | 7.75 | 7.75 | |||||
| EBIT/Net interest | x | -1.97 | -1.97 | |||||
| Net debt/market cap | % | 26.03% | 177.59% | |||||
| Net debt/Equity | x | 0.39 | 0.60 | |||||
| Gross debt/equity | x | 0.83 | 1.06 | |||||
Company overview
Aidigong Maternal & Child Health Limited functions as an investment holding entity, delivering a diverse portfolio of postpartum care and health-related services throughout both the People's Republic of China and Hong Kong. Its operational framework is segmented into Postpartum Care Services, the Health Industry, and other ancillary activities. The company's offerings are extensive, encompassing maternal and pediatric healthcare, medical anti-aging treatments, healthcare industry investments, and the development of healthcare properties. Furthermore, it facilitates trade in natural health foods and pharmaceutical products. Aidigong also extends its expertise to precision life healthcare, bio-medical technology, and various management services, alongside investment and financial solutions. The firm, previously known as Common Splendor International Health Industry Group Limited, transitioned to its current name in December 2019. Its corporate headquarters are situated in Kowloon Bay, Hong Kong.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Aidigong Maternal & Child Health Limited (0286.HK)
Aidigong Maternal & Child Health Limited functions as an investment holding entity, delivering a diverse portfolio of postpartum care and health-related services throughout both the People's Republic of China and Hong Kong. Its operational framework is segmented into Postpartum Care Services, the Health Industry, and other ancillary activities. The company's offerings are extensive, encompassing maternal and pediatric healthcare, medical anti-aging treatments, healthcare industry investments, and the development of healthcare properties. Furthermore, it facilitates trade in natural health foods and pharmaceutical products. Aidigong also extends its expertise to precision life healthcare, bio-medical technology, and various management services, alongside investment and financial solutions. The firm, previously known as Common Splendor International Health Industry Group Limited, transitioned to its current name in December 2019. Its corporate headquarters are situated in Kowloon Bay, Hong Kong.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free